ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
ADMA Biologics's price to sales ratio was 5.8× on Nov 11, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 2.8× to 14.1×, with a median of 5.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.8× | −3.1 |
| 2025 | Dec 31, 2025 | 8.9× | −1.7 |
| 2024 | Dec 31, 2024 | 10.6× | +6.2 |
| 2023 | Dec 29, 2023 | 4.4× | −1.5 |
| 2022 | Dec 30, 2022 | 5.9× | +3.0 |
| 2021 | Dec 31, 2021 | 2.8× | −1.5 |
| 2020 | Dec 31, 2020 | 4.3× | −6.8 |
| 2019 | Dec 31, 2019 | 11.1× | +6.7 |
| 2018 | Dec 31, 2018 | 4.4× | +0.5 |
| 2017 | Dec 29, 2017 | 3.9× | −2.8 |
| 2016 | Dec 30, 2016 | 6.7× | −7.3 |
| 2015 | Dec 31, 2015 | 14.0× | −7.3 |
| 2014 | Dec 31, 2014 | 21.4× | +6.9 |
| 2013 | Dec 31, 2013 | 14.5× | – |
See a number that looks wrong?